These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Phenytoin and fosphenytoin: a model of cost and clinical outcomes. Armstrong EP; Sauer KA; Downey MJ Pharmacotherapy; 1999 Jul; 19(7):844-53. PubMed ID: 10417033 [TBL] [Abstract][Full Text] [Related]
5. Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin. DeToledo JC; Lowe MR; Rabinstein A; Villaviza N Epilepsia; 2001 Feb; 42(2):288. PubMed ID: 11240605 [No Abstract] [Full Text] [Related]
6. Inappropriate fosphenytoin use in the ED. Johnson J; Wrenn K Am J Emerg Med; 2001 Jul; 19(4):293-4. PubMed ID: 11447516 [TBL] [Abstract][Full Text] [Related]
7. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Perron R Neurology; 2005 Apr; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15858865 [No Abstract] [Full Text] [Related]
8. Pfizer is fined £84m for "exploiting opportunity" to hike price of phenytoin. Hawkes N BMJ; 2016 Dec; 355():i6628. PubMed ID: 27932377 [No Abstract] [Full Text] [Related]
9. Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department. Rudis MI; Touchette DR; Swadron SP; Chiu AP; Orlinsky M Ann Emerg Med; 2004 Mar; 43(3):386-97. PubMed ID: 14985668 [TBL] [Abstract][Full Text] [Related]
12. Reactions to fosphenytoin editorial and review article. Hopefl A Am J Health Syst Pharm; 1997 Feb; 54(4):445. PubMed ID: 9043574 [No Abstract] [Full Text] [Related]
13. Reactions to fosphenytoin editorial and review article. Paloucek FP Am J Health Syst Pharm; 1997 Feb; 54(4):449. PubMed ID: 9043575 [No Abstract] [Full Text] [Related]
14. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department. Touchette DR; Rhoney DH Pharmacotherapy; 2000 Aug; 20(8):908-16. PubMed ID: 10939551 [TBL] [Abstract][Full Text] [Related]
15. Reactions to fosphenytoin editorial and review article. Orr J Am J Health Syst Pharm; 1997 Feb; 54(4):442, 445. PubMed ID: 9043573 [No Abstract] [Full Text] [Related]
16. Reactions to fosphenytoin editorial and review article. Matheson C Am J Health Syst Pharm; 1997 Feb; 54(4):441-2. PubMed ID: 9043571 [No Abstract] [Full Text] [Related]
17. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Marchetti A; Magar R; Fischer J; Sloan E; Fischer P Clin Ther; 1996; 18(5):953-66. PubMed ID: 8930434 [TBL] [Abstract][Full Text] [Related]
18. Fosphenytoin safety and economics. Paloucek FP Am J Health Syst Pharm; 1996 Nov; 53(22):2702. PubMed ID: 8931811 [No Abstract] [Full Text] [Related]
19. Pfizer could face large fine over pricing of generic phenytoin. Hawkes N BMJ; 2016 Nov; 355():i6401. PubMed ID: 27895057 [No Abstract] [Full Text] [Related]
20. Effectiveness and cost of generic versus brand-name valproic acid. Coulter DL Ment Retard; 1997 Dec; 35(6):472-5. PubMed ID: 9425877 [No Abstract] [Full Text] [Related] [Next] [New Search]